OnCo

Stay in the loop

Leave your email and OnCo will write when something big changes in cancer research. No spam, one click to unsubscribe.

Email updates open shortly. Until then, press Watch on any page to keep it on your list.

drugsTreatmentPhase 2

Samuraciclib

aka ICEC0942, CT7001

Samuraciclib is an oral cdk inhibitor from Pfizer, in registered phase 2 trials for metastatic cancer, HR-positive / HER2-negative breast cancer.